NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
VERAXA Biotech (VRXA) BiTAC Pipeline and Partnering Strategy FAQ
VERAXA Biotech provided a corporate update highlighting progress in its proprietary BiTAC platform, with four T-cell engager programs and two bispecific ADC programs in the pipeline, aiming to advance lead candidate VXA-102 to IND/CTA readiness by early 2028 while seeking partnerships for non-BiTAC assets.
The update highlights the advancement of its proprietary BiTAC platform, including four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific ADC programs, and two non-BiTAC assets available for partnering.
The BiTAC platform is differentiated and has generated strong industry interest from potential pharmaceutical partners, as evidenced by recent partnering discussions at scientific meetings like the BIO International Convention.
VERAXA plans to monetize selected non-BiTAC programs to help finance future development, while prioritizing investment in its BiTAC portfolio.
The company aims to advance lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
The full press release is available at https://ibn.fm/xTF5q, and the latest news and updates can be found in the company's newsroom at https://ibn.fm/VRXA.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
The pipeline includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.